SI20852B - Mezoprogestini (modulatorji receptorja progesterona) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj - Google Patents
Mezoprogestini (modulatorji receptorja progesterona) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj Download PDFInfo
- Publication number
- SI20852B SI20852B SI200020042A SI200020042A SI20852B SI 20852 B SI20852 B SI 20852B SI 200020042 A SI200020042 A SI 200020042A SI 200020042 A SI200020042 A SI 200020042A SI 20852 B SI20852 B SI 20852B
- Authority
- SI
- Slovenia
- Prior art keywords
- prevention
- treatment
- mesoprogestins
- disorders
- progesterone receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Pričujoči izum opisuje uporabo mezoprogestinov, novega razreda modulatorjev receptorja progesterona (PRM) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj: a) za zdravljenje ginekoloških motenj, kot so endometrioza, maternični fibroidi, postoperativne peritonealne adhezije, disfunkcijska krvavitev (metroragija, menoragija) in dismenoreja; b) za preprečevanje ginekoloških motenj, kot so postoperativne, peritonealne adhezije, disfunkcijska krvavitev maternice (metroragija,menoragija) in dismenoreja; in c) postopek zdravljenja in preprečevanja zgoraj omenjenih motenj pri samici, prednostno ženski, ki potrebuje zdravljenje in preprečevanje ene ali več teh motenj z učinkovito količino mezoprogestina. Mezoprogestini so definirani kot spojine, ki imajo tako agonistične kot antagonistične aktivnosti na receptorju progesterona (PR) in vivo. Stabilizirajo funkcijo PR na intermediatni stopnji agonista in antagonista. Ustreznih funkcijskih stanj ne moremo doseči s progestini aliantiprogestini. Dnevni odmerek mezoprogestina je 0,5 do 100 mg, prednostno 5,0 do 50 mg in najbolj prednostno 10 do 25 mg. J867, J912, J956 in J1042 so prednostni mezoprogestini v smislu izuma.
Claims (3)
1/1 Sl 20852 Mezoprogestini za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj Patentni zahtevki 1. Uporaba učinkovite količine mezoprogestina, izbranega iz skupine, ki jo sestavljajo J867, J912 in J956 za izdelavo zdravila za zdravljenje endometrioze, uterinih fibroidov, disfunkcijske krvavitve maternice (metroragija, menoragija) in dismenoreje, pri čemer je dnevni odmerek mezoprogestina 5,0 do 50 mg.
2. Uporaba učinkovite količine mezoprogestina, izbranega iz skupine, ki jo sestavljajo J867, J912 in J956 za izdelavo zdravila za preprečevanje disfunkcijske krvavitve maternice (metroragija, menoragija) in dismenoreje, pri čemer je dnevni odmerek mezoprogestina 5,0 do 50 mg.
3. Uporaba po zahtevku 1 ali 2, kjer je dnevni odmerek mezoprogestina 10 do 25 mg.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38614199A | 1999-08-31 | 1999-08-31 | |
| PCT/US2000/023770 WO2001015679A2 (en) | 1999-08-31 | 2000-08-31 | Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI20852A SI20852A (sl) | 2002-10-31 |
| SI20852B true SI20852B (sl) | 2009-06-30 |
Family
ID=23524338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200020042A SI20852B (sl) | 1999-08-31 | 2000-08-31 | Mezoprogestini (modulatorji receptorja progesterona) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1229906B1 (sl) |
| JP (1) | JP2003535029A (sl) |
| KR (3) | KR100864547B1 (sl) |
| AR (1) | AR025457A1 (sl) |
| AT (1) | ATE375160T1 (sl) |
| AU (1) | AU781840B2 (sl) |
| BG (1) | BG65817B1 (sl) |
| BR (1) | BR0014161A (sl) |
| CA (1) | CA2382580C (sl) |
| CO (1) | CO5200772A1 (sl) |
| CZ (1) | CZ2002704A3 (sl) |
| DE (1) | DE60036723T2 (sl) |
| DK (1) | DK1229906T3 (sl) |
| EA (1) | EA007854B1 (sl) |
| EE (1) | EE05172B1 (sl) |
| ES (1) | ES2295050T3 (sl) |
| HR (1) | HRP20020267A2 (sl) |
| HU (1) | HUP0202429A3 (sl) |
| IL (1) | IL148416A0 (sl) |
| LT (1) | LT5034B (sl) |
| LV (1) | LV12941B (sl) |
| ME (1) | MEP13808A (sl) |
| MX (1) | MXPA02002191A (sl) |
| NO (1) | NO20020999L (sl) |
| NZ (1) | NZ517471A (sl) |
| PE (1) | PE20010578A1 (sl) |
| PL (1) | PL198790B1 (sl) |
| PT (1) | PT1229906E (sl) |
| RO (1) | RO122179B1 (sl) |
| RS (1) | RS50283B (sl) |
| SI (1) | SI20852B (sl) |
| SK (1) | SK287192B6 (sl) |
| UA (1) | UA78184C2 (sl) |
| WO (1) | WO2001015679A2 (sl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10236405A1 (de) | 2002-08-02 | 2004-02-19 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie |
| ATE338763T1 (de) * | 2002-08-02 | 2006-09-15 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie |
| US20040097591A1 (en) * | 2002-11-18 | 2004-05-20 | Kristof Chwalisz | Use of selective progesterone receptor modulators for the treatment of androgen deficiency |
| RU2301691C1 (ru) * | 2005-12-20 | 2007-06-27 | Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Российской академии медицинских наук | Способ восстановительного лечения женщин репродуктивного возраста с тазовыми перитонеальными спайками с фиксированной или субфиксированной ретродевиацией матки |
| DE102007011105A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose |
| RU2339392C1 (ru) * | 2007-05-21 | 2008-11-27 | Федеральное Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Росмедтехнологий | Способ остановки маточных кровотечений в пубертатном периоде |
| EP2455077B1 (en) * | 2009-06-17 | 2014-06-11 | National University Corporation Kumamoto University | Prophylactic and/or therapeutic agent for dysmenorrhea |
| US8399432B2 (en) * | 2009-10-27 | 2013-03-19 | Lipogen Ltd. | Compositions and methods of treatment for alleviating premenstrual syndrome symptoms |
| WO2021061847A1 (en) * | 2019-09-23 | 2021-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treatments to prolong gestation and complications of menstruation or gestation |
| US12426782B2 (en) | 2020-11-06 | 2025-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and temporal alignment methods for evaluation of gestational age and time to delivery |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3633244A1 (de) | 1986-09-26 | 1988-03-31 | Schering Ag | Antigestagene zur hemmung der uterinen prostaglandinsynthese |
| DE4332283A1 (de) * | 1993-09-20 | 1995-04-13 | Jenapharm Gmbh | Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE4332284C2 (de) | 1993-09-20 | 1997-05-28 | Jenapharm Gmbh | 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US5681817A (en) * | 1994-02-04 | 1997-10-28 | The Medical College Of Hampton Roads | Treatment of ovarian estrogen dependent conditions |
| US5576310A (en) * | 1994-09-20 | 1996-11-19 | Jenapharm Gmbh | 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds |
| CA2208347A1 (en) * | 1994-12-22 | 1996-06-27 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| US5693646A (en) * | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| KR100370908B1 (ko) | 1995-02-02 | 2003-04-10 | 쉐링 악티엔게젤샤프트 | 기능부전성자궁출혈치료용약제의제조에유용한프로게스테론길항제 |
| DE19604231A1 (de) * | 1996-01-29 | 1997-07-31 | Schering Ag | Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen |
| AU710139B2 (en) * | 1996-05-01 | 1999-09-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | 21-substituted progesterone derivatives as new antiprogestational agents |
| WO1998005679A2 (en) * | 1996-08-05 | 1998-02-12 | Duke University | Mixed agonists of the progesterone receptor and assays therefor |
| DE19809845A1 (de) * | 1998-03-03 | 1999-09-09 | Jenapharm Gmbh | S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| TR200102041T2 (tr) * | 1999-01-14 | 2001-12-21 | Bayer Corporation | Progesteron reseptör bağlama aktif maddeleri olarak ikameli 2-arilimino heterosaykıllar |
| HK1043788A1 (zh) * | 1999-05-04 | 2002-09-27 | American Home Products Corporation | 四環黃體酮受體調節劑化合物及方法 |
-
2000
- 2000-08-31 DE DE60036723T patent/DE60036723T2/de not_active Expired - Lifetime
- 2000-08-31 CO CO00065515A patent/CO5200772A1/es not_active Application Discontinuation
- 2000-08-31 UA UA2002032430A patent/UA78184C2/uk unknown
- 2000-08-31 RO ROA200200229A patent/RO122179B1/ro unknown
- 2000-08-31 PT PT00957914T patent/PT1229906E/pt unknown
- 2000-08-31 CA CA002382580A patent/CA2382580C/en not_active Expired - Lifetime
- 2000-08-31 ME MEP-138/08A patent/MEP13808A/xx unknown
- 2000-08-31 EP EP00957914A patent/EP1229906B1/en not_active Expired - Lifetime
- 2000-08-31 HR HR20020267A patent/HRP20020267A2/xx not_active Application Discontinuation
- 2000-08-31 HU HU0202429A patent/HUP0202429A3/hu unknown
- 2000-08-31 DK DK00957914T patent/DK1229906T3/da active
- 2000-08-31 RS YUP-140/02A patent/RS50283B/sr unknown
- 2000-08-31 AT AT00957914T patent/ATE375160T1/de not_active IP Right Cessation
- 2000-08-31 EA EA200200282A patent/EA007854B1/ru not_active IP Right Cessation
- 2000-08-31 KR KR1020077011455A patent/KR100864547B1/ko not_active Expired - Fee Related
- 2000-08-31 NZ NZ517471A patent/NZ517471A/en unknown
- 2000-08-31 SI SI200020042A patent/SI20852B/sl not_active IP Right Cessation
- 2000-08-31 WO PCT/US2000/023770 patent/WO2001015679A2/en not_active Ceased
- 2000-08-31 IL IL14841600A patent/IL148416A0/xx unknown
- 2000-08-31 SK SK299-2002A patent/SK287192B6/sk unknown
- 2000-08-31 EE EEP200200104A patent/EE05172B1/xx not_active IP Right Cessation
- 2000-08-31 KR KR1020027002790A patent/KR100755109B1/ko not_active Expired - Fee Related
- 2000-08-31 PE PE2000000893A patent/PE20010578A1/es not_active Application Discontinuation
- 2000-08-31 BR BR0014161-5A patent/BR0014161A/pt not_active Application Discontinuation
- 2000-08-31 KR KR1020087016247A patent/KR20080066095A/ko not_active Withdrawn
- 2000-08-31 AU AU69466/00A patent/AU781840B2/en not_active Ceased
- 2000-08-31 CZ CZ2002704A patent/CZ2002704A3/cs unknown
- 2000-08-31 AR ARP000104538A patent/AR025457A1/es unknown
- 2000-08-31 JP JP2001519893A patent/JP2003535029A/ja active Pending
- 2000-08-31 ES ES00957914T patent/ES2295050T3/es not_active Expired - Lifetime
- 2000-08-31 PL PL353930A patent/PL198790B1/pl not_active IP Right Cessation
-
2002
- 2002-02-26 BG BG106442A patent/BG65817B1/bg unknown
- 2002-02-28 MX MXPA02002191A patent/MXPA02002191A/es active IP Right Grant
- 2002-02-28 NO NO20020999A patent/NO20020999L/no not_active Application Discontinuation
- 2002-03-21 LT LT2002031A patent/LT5034B/lt not_active IP Right Cessation
- 2002-03-28 LV LVP-02-53A patent/LV12941B/lv unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO964155L (no) | Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger | |
| PT792152E (pt) | Metodos de contracepcao | |
| SI20852B (sl) | Mezoprogestini (modulatorji receptorja progesterona) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj | |
| AR011480A1 (es) | ACIL-ANILIDAS SUSTITUIDAS CON RADICALES (HETERO) CICLICOS, NO ESTEROIDALES, CON ACTIVIDAD GESTÁGENA Y ANDRoGENA MIXTA. | |
| CA2420348A1 (en) | Non-hormonal vaginal contraceptive | |
| ATE451123T1 (de) | Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie | |
| WO2004000225A3 (en) | Use of thio-oxindole derivatives in treatment of hormone-related conditions | |
| BR0013009A (pt) | Uso de antagonistas de cgrp e de inibidores de liberação de cgrp para combate a jatos quentes menopáusicos | |
| BR0117123A (pt) | Dispositivo de retenção gástrica expansìvel | |
| EP3558316A1 (de) | Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind | |
| LT2002035A (lt) | Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip moterų kontraceptikų komponentas | |
| CL2003001544A1 (es) | Compuestos derivados de 5-cicloalquenil-5h-cromeno[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, l | |
| SI20851B (sl) | Mezoprogestini (modulatorji receptorja progesterona) kot komponenta pripravkov za nadomestno zdravljenje s hormoni (NZH) | |
| EA200702604A1 (ru) | Производные бензофуранона как нестероидные модуляторы рецептора прогестерона | |
| CL2003001545A1 (es) | Compuestos derivados de 7,9-difluoro-5h-cromeno-[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, lei | |
| WO2003099322A3 (en) | Il-11 derivatives and therapeutic uses thereof | |
| WO2003035059A3 (en) | Spermicides | |
| AR028470A1 (es) | Ariltiofeno agonistas de vasopresina, el uso de los mismos para manufactura de un medicamento y composicion farmaceutica | |
| BR0010070A (pt) | Uso de org 33245, kit contraceptivo, meio combinado para a dosagem de um progestogênio e um antiprogestogênio, e, métodos de contracepção, e de tratamento de sangramento uterino irregular ou de ruptura em uma fêmea utilizando uma preparação somente de progestogênio | |
| WO2000032176A3 (en) | Use of 17-ketosteroids for the treatment of toxoplasmosis and cryptosporidosis | |
| Luukkainen | THERAPEUTIC USE OF LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM, MIRENA | |
| Teplova et al. | Etiology and character of systemic immunity disturbances in tuboperitoneal sterility | |
| TH94755B (th) | สารผสมทางเภสัชกรรมเพื่อการคุมกำเนิด และ สำหรับลดความเสี่ยงความผิดปกติที่เป็นมาแต่กำเนิด | |
| WO2000059447A3 (fr) | Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SP73 | Change of data on owner |
Owner name: SCHERING AKTIENGESELLSCHAFT; DE Effective date: 20041118 |
|
| IF | Valid on the event date | ||
| OU02 | Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims |
Effective date: 20090422 |
|
| SP73 | Change of data on owner |
Owner name: BAYER SCHERING PHARMA AG; DE Effective date: 20090325 |
|
| KO00 | Lapse of patent |
Effective date: 20110413 |